CVD Risk Profile in Children With HCM

Sponsor
University of Alberta (Other)
Overall Status
Recruiting
CT.gov ID
NCT05510180
Collaborator
(none)
50
10
45.3
5
0.1

Study Details

Study Description

Brief Summary

Hypertrophic cardiomyopathy is a disease of the heart muscle that causes the heart to become thicker and this thickness places children at risk of heart rhythm problems, heart failure and sudden death.To decrease the risk of sudden death, health care providers generally counsel that the patient should stop all intense physical activity. While this recommendation may decrease the risk of sudden death it is unclear what the long term impact of reduced physical activity is on cardiovascular health in children with HCM.

Cardiovascular (CV) disease is a disease of the heart and blood vessels and is the cause of heart attacks in adults. There are many risk factors for the development of CV disease including genetics, medical conditions and lifestyle choices. While some studies in adults suggest that patients with HCM are at higher risk of poor cardiovascular health, this has not yet been assessed in children. Although, CV disease is generally thought of to be a disease of adults, there is a lot of information that suggests the development of CV disease starts early in life and therefore by promoting heart healthy lifestyles in children, it is possible that these children will becomes healthier adults.

The goal of this project is to assess risk factors for CV disease in a population of children with HCM at the two largest pediatric cardiac programs in Canada. This assessment will be to look at factors we can measure (e.g., weight, cholesterol levels) and patients' and families' perceptions of what it means to be heart healthy. It is hoped that through this project risk factors for heart disease, and poor "heart healthy" lifestyles choices, will be identified in order to develop strategies to decrease these risk factors in patients with HCM. With a better understanding of the families' perceptions of heart healthy behaviours, educational tools and resources for cardiovascular health promotion in patients with HCM can be developed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy with the hallmark feature of left ventricular hypertrophy primarily involving the ventricular septum. It is associated with an increased risk of arrhythmias and sudden cardiac death (SC) [Maron et al., 2016]. It is the most common genetic heart disease, with a prevalence of up to 1 in 200 in the general population.

    It is widely acknowledged that regular physical activity is important for long-term CV health in the general population. Childhood obesity is on the rise in the general population and physicians may be compounding the risk in children with HCM due to the activity restrictions imposed on them. Given the significant emphasis placed on what physical activities patients with HCM should avoid, physicians may not be effectively communicating the importance of maintaining a heart healthy lifestyle, including the importance of regular physical activity, on long-term CV health. This theory could explain the high levels of inactivity and obesity seen in the adult population of individuals with HCM, which have important consequences on long-term health and well-being.

    Little research has been done to examine the other markers of CV health in the adult population. In addition, there have not been any studies evaluating the CV disease risk profile of children and adolescents with HCM and whether the phenomenon seen in the adult population is also seen in pediatric patients. This study will fill an important gap which will allow for the development of safe interventions in this unique patient population focused on promoting life-long CV health.

    The primary aims of the study are:
    1. To describe the CV disease risk behaviors and CV disease risk profile of children with HCM.

    2. To determine if children with HCM are at greater risk for acquired CV disease compared to the general population.

    The secondary aim of the study are:
    1. To identify barriers to a heart healthy lifestyle.

    2. To identify both the children's and families' perception of a heart healthy lifestyle.

    This study will employ multiple methods. The quantitative component will be a prospective cross-sectional study undertaken at two centers in Canada with a dedicated Heart Function and Cardiomyopathy Department. The quantitative component will be a prospective cross-sectional study undertaken at across pediatric cardiac centers in Canada who look after children with HCM.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Cardiovascular Disease Risk Profile in Children With Hypertrophic Cardiomyopathy
    Actual Study Start Date :
    May 21, 2019
    Anticipated Primary Completion Date :
    Feb 28, 2023
    Anticipated Study Completion Date :
    Feb 28, 2023

    Outcome Measures

    Primary Outcome Measures

    1. CV disease risk factors [2 weeks - Visit 2]

      Healthy Hearts School Program Questionnaire

    2. CV disease risk behaviours [2 weeks - Visit 2]

      Healthy Hearts School Program Questionnaire

    3. Acquired CV disease [2 weeks - Visit 2]

      Healthy Hearts School Program Questionnaire

    Secondary Outcome Measures

    1. Heart healthy lifestyle barriers [Baseline - Visit 1]

      Self-Efficacy for Exercise Scale

    2. Heart healthy lifestyle barriers [Baseline - Visit 1]

      PedsQL (Pediatric Quality of Life Inventory and Pediatric Quality of Life Inventory: Cardiac Module)

    3. Child's perception of heart healthy lifestyle [Baseline - Visit 1]

      Habitual Activity Estimation Scale (HAES)

    4. Parents' perception of heart healthy lifestyle [Baseline - Visit 1]

      Habitual Activity Estimation Scale (HAES)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years to 19 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients between 10 and 19 years of age meeting the diagnostic criteria for primary hypertrophic cardiomyopathy set in the American Heart Association guideline and their families will be included.

    2. Parents and/or guardians of children 10-19 years of age with hypertrophic cardiomyopathy.

    3. English speaking -

    Exclusion Criteria:
    1. Secondary hypertrophic cardiomyopathy

    2. Structural congenital heart defects that has the potential to limit physical ability

    3. Significant physical disability as identified by the cardiologist that limits physical activity ability (e.g., neuromuscular disease)

    4. Significant cognitive disorder or language barrier as identified by the cardiologist that would limit the completion of an English-language survey

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Stollery Children's Hospital Edmonton Alberta Canada T6G 2B7
    2 BC Children's Hospital Vancouver British Columbia Canada V6H 3N1
    3 Children's Hospital Winnipeg Manitoba Canada R3A 1S1
    4 IWK Health Centre Halifax Nova Scotia Canada B3K 6R8
    5 Hospital for Sick Children Toronto Ontario Canada M5G 1X8
    6 CHU Sainte-Justine Montreal Quebec Canada H3T 1C5
    7 Montreal Children's Hospital Montreal Quebec Canada H4A 3J1
    8 Centre Hospitalier de l'Université Laval Quebec City Quebec Canada G1V 4G2
    9 Centre Hospitalier Universitaire de Sherbrooke Sherbrooke Quebec Canada J1H 5N4
    10 Jim Pattison Children's Hospital Saskatoon Saskatchewan Canada S7N 0W8

    Sponsors and Collaborators

    • University of Alberta

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Alberta
    ClinicalTrials.gov Identifier:
    NCT05510180
    Other Study ID Numbers:
    • Pro00083230
    First Posted:
    Aug 22, 2022
    Last Update Posted:
    Aug 22, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 22, 2022